



2/24/2022

### Notice Regarding Offer of Refunds to 340B Covered Entities

As a result of a recent Health Resources and Services Administration (“HRSA”), Office of Pharmacy Affairs (“OPA”) audit, Akorn Operating Company LLC (“Akorn”) has identified certain instances where the appropriate 340B Ceiling Price may not have been offered or available to all Covered Entities for the NDCs referenced below during the time period of January 1, 2019 through December 31, 2021.

Akorn has recalculated the 340B Ceiling Prices and has determined that a refund is or may be owed to 340B Covered Entities that purchased any of the below NDCs during the time period of January 1, 2019 through December 31, 2021. Akorn will be working with Apexus, LLC (“Apexus”), the 340B Prime Vendor, to validate wholesaler pharmacy account information for each covered entity. Once validated, Apexus will work with the wholesalers to facilitate the processing of credit for the overpayments that the covered entity was charged during the specified periods. If an active wholesaler account cannot be identified within two weeks after the initial communication, then Apexus will work to issue a check to those entities.

<b><u>NDC 11</u></b>	<b><u>Product Description</u></b>
50383-0261-61	Dorzolamide HCl/Timolol Maleate Ophth Solution .02mL x 60
17478-0082-90	Ropivacaine HCl Injection, USP 0.2% 100mL
17478-0082-92	Ropivacaine HCl Injection, USP 0.2% 200mL
17478-0768-30	Aminocaproic Acid Tablets 500mg
17478-0769-30	Aminocaproic Acid Tablets 1000mg
17478-0015-02	Dicyclomine HCl Injection 2mL x 5
50383-0265-05	Loteprednol Etabonate Ophthalmic Suspension 0.5% 5mL
50383-0265-10	Loteprednol Etabonate Ophthalmic Suspension 0.5% 10mL
50383-0265-15	Loteprednol Etabonate Ophthalmic Suspension 0.5% 15mL
50383-0272-01	Diclofenac Sodium Topical Gel 1%

17478-0447-08	Aminocaproic Acid Oral Solution
50383-0942-30	Azelastine HCl Nasal Spray 0.15%, 30mL
61748-0480-30	Betamethasone Dipropionate Lotion USP (Augmented) 30mL
61748-0480-60	Betamethasone Dipropionate Lotion USP (Augmented) 60mL
50383-0943-23	Olopatadine HCl Nasal Spray 30.5gm
17478-0189-24	Timolol Maleate Ophthalmic Solution, USP 60 x 0.3mL
50383-0912-03	Bimatoprost Ophthalmic Solution 0.03% 3mL
50383-0912-05	Bimatoprost Ophthalmic Solution 0.03% 5mL
17478-0830-05	Loteprednol Etabonate Ophthalmic Gel 0.5% 5gm
50383-0339-13	Acet Codeine Phos Oral Sol CV 120mg/12mg per12.5mL,40UD Cups
50383-0337-06	Acet Codeine Phos Oral Sol CV 120mg/12mg per12.5mL,40UD Cups
50383-0341-35	Lidocaine Ointment 5% 35.44g Tube
50383-0349-11	Docu Liquid 10mL UD; 100PK (Docusate Sodium 100mg/10mL)
50383-0312-84	Oxcarbazepine Oral Suspension, USP 300mg/5mL

If a Covered Entity believes they are due a refund and are not contacted by Apexus by March 25, 2022, you may contact Akorn at the following email address: 340B@Akorn.com.

Akorn has asked HRSA to post this Notice on HRSA's public website to ensure transparency to all 340B Covered Entities regarding the Ceiling Prices for all NDCs identified above and to offer a refund to any of the 340B Covered Entities that may have purchased the above NDCs during the relevant time periods. Please direct any questions and/or requests for additional information to Akorn at the following email address: 340B@Akorn.com.